Prognostic significance of CEBPA mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML study group Ulm.

被引：0
|
作者：
Frohling, S [1 ]
Schlenk, RF [1 ]
Stolze, I [1 ]
Bihlmayr, J [1 ]
Kreitmeier, S [1 ]
Tobis, K [1 ]
Dohner, H [1 ]
Dohner, K [1 ]
机构：
[1] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2962
引用
收藏
页码：748A / 748A
页数：1
相关论文
共 50 条
  • [41] Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia
    Papaioannou, Dimitrios
    Nicolet, Deedra
    Volinia, Stefano
    Mrozek, Krzysztof
    Yan, Pearlly
    Bundschuh, Ralf
    Carroll, Andrew J.
    Kohlschmidt, Jessica
    Blum, William
    Powell, Bayard L.
    Uy, Geoffrey L.
    Kolitz, Jonathan E.
    Wang, Eunice S.
    Eisfeld, Ann-Kathrin
    Orwick, Shelley J.
    Lucas, David M.
    Caligiuri, Michael A.
    Stone, Richard M.
    Byrd, John C.
    Garzon, Ramiro
    Bloomfield, Clara D.
    HAEMATOLOGICA, 2017, 102 (08) : 1391 - 1400
  • [42] Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AM L Study Group (AMLSG)
    Theis, Frauke
    Corbacioglu, Andrea
    Gaidzik, Verena I.
    Paschka, Peter
    Spaeth, Daniela
    Rehrl, Michaela
    Bullinger, Lars
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Koehne, Claus-Henning
    Germing, Ulrich
    Brossart, Peter
    Horst, Heinz-August
    Haase, Detlef
    Goetze, Katharina S.
    Ringhoffer, Mark
    Fiedler, Walter
    Nachbaur, David
    Kindler, Thomas
    Held, Gerhard
    Krauter, Juergen
    Heuser, Michael
    Ganser, Arnold
    Doehner, Hartmut
    Schlenk, Richard F.
    Doehner, Konstanze
    BLOOD, 2013, 122 (21)
  • [43] Prognostic significance of WBC, age, and cytogenetics in patients with core binding factor acute myeloid leukemia (CBF-AML): A comparative study from the French AML Intergroup.
    Delaunay, J
    Leblanc, T
    Blaise, D
    Fenaux, P
    Huguet-Rigal, F
    Witz, F
    Pigneux, A
    Thomas, X
    Auvrignon, A
    Colombat, P
    Lioure, B
    Van den Akker, J
    Mugneret, F
    Bastard, C
    Dastugue, N
    Castaigne, S
    Reiffers, J
    Leverger, G
    Harousseau, JL
    Dombret, H
    BLOOD, 2002, 100 (11) : 748A - 748A
  • [44] Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study (vol 26, pg 5078, 2008)
    Marcucci
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 6021 - 6021
  • [45] Prognostic significance of partial tandem duplications of the MLL gene in acute myeloid leukemia with normal cytogenetics:: A study within a multicenter treatment trial.
    Döhner, K
    Ulrich, R
    Liebisch, C
    Fröhling, S
    Schlenk, RF
    Döhner, H
    BLOOD, 1999, 94 (10) : 499A - 499A
  • [46] Prevalence and prognostic significance of FLT3 mutations in acute myeloid leukemia: Association of ITDs with poor outcome in patients with normal cytogenetics.
    Palmisano, Michela
    Ottaviani, Emanuela
    Grafone, Tiziana
    Testoni, Nicoletta
    Paolini, Stefania
    Rondoni, Michela
    Baccarani, Michele
    Martinelli, Giovanni
    BLOOD, 2006, 108 (11) : 571A - 571A
  • [47] Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG
    Pogosova-Agadjanyan, Era L.
    Kopecky, Kenneth J.
    Petersdorf, Stephen
    Erba, Harry Paul
    Stone, Richard M.
    Meshinchi, Soheil
    Nevill, Thomas J.
    Radich, Jerald P.
    Stenke, Leif
    Slovak, Marilyn L.
    Stuart, Robert K.
    Tallman, Martin S.
    Willman, Cheryl L.
    Mortensen, Rebecca M.
    Wentz, Breanna L.
    Appelbaum, Frederick R.
    Stirewalt, Derek L.
    BLOOD, 2011, 118 (21) : 1080 - 1080
  • [48] Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:: interaction with other gene mutations
    Döhner, K
    Schlenk, RF
    Habdank, M
    Scholl, C
    Rücker, FG
    Corbacioglu, A
    Bullinger, L
    Fröhling, S
    Döhner, H
    BLOOD, 2005, 106 (12) : 3740 - 3746
  • [49] Prognostic Impact of Neutropenia Period in Patients with Acute Myeloid Leukemia (AML) Enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study
    Aoki, T.
    Takahashi, H.
    Tanaka, S.
    Shiba, N.
    Hasegawa, D.
    Iwamoto, S.
    Terui, K.
    Moritake, H.
    Nakayama, H.
    Shimada, A.
    Koh, K.
    Goto, H.
    Kosaka, Y.
    Saito, A. Moriya
    Horibe, K.
    Kinoshita, A.
    Tomizawa, D.
    Tawa, A.
    Taga, T.
    Adachi, S.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S30 - S31
  • [50] DNMT3A MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML): MONITORING OF MINIMAL RESIDUAL DISEASE (MRD). A STUDY OF THE AML STUDY GROUP (AMLSG)
    Gaidzik, V. I.
    Weber, D.
    Paschka, P.
    Krieger, S.
    Kaumanns, A.
    Kroenke, J.
    Kapp-Schwoerer, S.
    Koehne, C. -H.
    Horst, H. -A.
    Schmidt-Wolf, I.
    Held, G.
    Kuendgen, A.
    Ringhoffer, M.
    Goetze, K.
    Kindler, T.
    Fiedler, W.
    Wattad, M.
    Corbacioglu, A.
    Bullinger, L.
    Schlegelberger, B.
    Thol, F.
    Heuser, M.
    Ganser, A.
    Schlenk, R. F.
    Doehner, H.
    Doehner, K.
    HAEMATOLOGICA, 2015, 100 : 163 - 163
12345